JPRN-UMIN000014986已完成未知
Randomized, multicenter, open, two-arm parallel group trial of Oral myofunctional training for Clinical evidence to dementia. - ORACLE trial for dementia
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Person who is mechanically ventilated 2) Person who has serious conditions in the oral cavity 3) In case the doctor finds any difficulty for participation
研究者
相似试验
进行中（未招募）
不适用
Randomised, multi-center, open-label, parallel-group study comparing adalimumab (Humira[R]) 40 mg s.c. eow versus infliximab (Remicade[R]) 3 mg/kg i.v. every 6. week in RA patients with unsustainable clinical response to infliximab 3 mg/kg every 8. week - The SWITCH StudyRheumatoid arthritisEUCTR2005-001633-14-SEHvidovre Hospital, Dept. Rheumatology112
进行中（未招募）
不适用
Randomised, multi-center, open-label, parallel-group study comparing adalimumab (Humira?) 40 mg s.c. eow versus infliximab (Remicade?) 3 mg/kg i.v. every 6. week in RA patients with unsustainable clinical response to infliximab 3 mg/kg every 8. week - The SWITCH StudyRheumatoid arthritisEUCTR2005-001633-14-DKHvidovre Hospital, Dept. Rheumatology112
进行中（未招募）
1 期
A study of an experimental new drug to treat diabetes.Subjects with type 2 diabetes mellitus who are being treated with metformin.MedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-000483-94-ESGlaxoSmithKline, S.A.
进行中（未招募）
1 期
A multi-centre, randomized, two-armed, parallel group and evaluator-blinded study of efficacy and safety of topical MOB015B in the treatment of mild to moderate distal subungual onychomycosis (DSO )Distal Subungual OnychomycosisMedDRA version: 20.0Level: PTClassification code 10030338Term: OnychomycosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001204-39-DEMoberg Pharma AB (publ)452
进行中（未招募）
1 期
A multi-centre, randomized, two-armed, parallel group and evaluator-blinded study of efficacy and safety of topical MOB015B in the treatment of mild to moderate distal subungual onychomycosis (DSO )EUCTR2016-001204-39-PLMoberg Pharma AB (publ)452